NATCO Pharma Limited

BSE:524816 Stock Report

Market Cap: ₹221.3b

NATCO Pharma Past Earnings Performance

Past criteria checks 6/6

NATCO Pharma has been growing earnings at an average annual rate of 33.3%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 19.1% per year. NATCO Pharma's return on equity is 27.2%, and it has net margins of 42.6%.

Key information

33.3%

Earnings growth rate

33.7%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate19.1%
Return on equity27.2%
Net Margin42.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How NATCO Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524816 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2445,63819,4485,6890
30 Jun 2443,49016,3655,2880
31 Mar 2440,02013,8835,3600
31 Dec 2338,29812,7785,5370
30 Sep 2335,63711,2745,6650
30 Jun 2329,6308,1524,7300
31 Mar 2327,0857,1534,7330
31 Dec 2224,0743,8905,0370
30 Sep 2224,7544,0715,1630
30 Jun 2224,1914,1544,5950
31 Mar 2219,4621,7005,0050
31 Dec 2116,8332,7354,6590
30 Sep 2114,7802,5584,4910
30 Jun 2118,9903,9314,2780
31 Mar 2120,5614,4094,5070
31 Dec 2021,7564,8205,0430
30 Sep 2023,0265,2385,0070
30 Jun 2019,8614,4043,7700
31 Mar 2019,1504,6084,7740
31 Dec 1919,1594,8753,8070
30 Sep 1919,9045,4253,7620
30 Jun 1920,4826,0603,6640
31 Mar 1920,9456,4444,4660
31 Dec 1824,0668,2354,0080
30 Sep 1824,1218,8153,8630
30 Jun 1822,9537,8383,5120
31 Mar 1821,8486,9623,4220
31 Dec 1719,8175,7303,1240
30 Sep 1720,8955,5062,9750
30 Jun 1721,6795,3232,5460
31 Mar 1720,2024,8602,6980
31 Dec 1617,6973,6802,0710
30 Sep 1613,6922,1132,1870
30 Jun 1612,4311,7481,9600
31 Mar 1610,4231,5491,9180
31 Dec 159,3551,4942,569126
30 Sep 158,5491,2662,432126
30 Jun 158,3901,2941,4540
31 Mar 157,3051,2931,2760
31 Dec 148,0891,0422,013143
30 Sep 148,1081,1991,977143
30 Jun 147,6481,1441,1870
31 Mar 147,3891,0271,847143

Quality Earnings: 524816 has high quality earnings.

Growing Profit Margin: 524816's current net profit margins (42.6%) are higher than last year (31.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524816's earnings have grown significantly by 33.3% per year over the past 5 years.

Accelerating Growth: 524816's earnings growth over the past year (72.5%) exceeds its 5-year average (33.3% per year).

Earnings vs Industry: 524816 earnings growth over the past year (72.5%) exceeded the Pharmaceuticals industry 20.5%.

Return on Equity

High ROE: 524816's Return on Equity (27.2%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 23:19
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NATCO Pharma Limited is covered by 27 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
Prashant NairAmbit Capital
null nullAnand Rathi Shares and Stock Brokers Limited